Entasis Therapeutics Holdings Inc.: management transactions · United States · SEC (Form 4)

About Entasis Therapeutics Holdings Inc.

Entasis Therapeutics Holdings Inc. was a U.S.-listed biopharmaceutical company on the NASDAQ market in the United States. For investors in French-speaking Europe, the most important context is that the company was acquired by Innoviva in 2022 and, to the best of current public information, no longer trades as an independent public company under the ETTX ticker. The company’s corporate structure was created in March 2018 as part of a reorganization that consolidated antibacterial development assets into a listed holding company, although its scientific roots go back further. Entasis was built around a clear therapeutic theme: novel treatments for serious bacterial infections, especially hard-to-treat and resistant Gram-negative pathogens. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1724344/000155837019002588/ettx-20181231x10k.htm?utm_source=openai)) The company was headquartered in Waltham, Massachusetts, United States, placing it in one of the main U.S. biotech clusters. Its core business was the discovery and development of innovative antibacterial products, with an emphasis on candidates intended for severe hospital and infectious-disease settings. In other words, Entasis was a pure-play R&D biotech rather than a diversified commercial pharmaceutical company. Its value proposition depended on advancing assets through preclinical and clinical development, then potentially securing regulatory approval or strategic partnerships. That model offers significant upside if a drug succeeds, but it also carries high scientific, regulatory, and financing risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1724344/000155837019002588/ettx-20181231x10k.htm?utm_source=openai)) From a product standpoint, Entasis focused on a pipeline of antibacterial candidates designed to address unmet medical needs in infections caused by drug-resistant bacteria. The company’s economics were therefore largely pipeline-driven, with little or no dependence on broad commercial sales diversification. For equity investors, this meant that the stock was typically highly sensitive to clinical data readouts, trial progress, financing events, and partnership announcements. That is characteristic of specialty biotech companies operating in a narrow therapeutic area with large unmet need but uncertain commercialization timing. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1724344/000155837019002588/ettx-20181231x10k.htm?utm_source=openai)) In competitive terms, Entasis operated in a crowded and demanding antibacterial innovation space, where larger pharmaceutical groups, clinical-stage biotech peers, and public-health urgency all shape the investment case. The company’s differentiation was its focus on resistant bacterial infections, a niche with significant medical relevance but difficult commercialization economics. Public filings also indicate that the business relied at times on external support and funding sources, underscoring the capital-intensive nature of its model. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1724344/000155837019002588/ettx-20181231x10k.htm?utm_source=openai)) The key recent corporate development was the 2022 acquisition by Innoviva for $2.20 per share, which effectively ended Entasis as a standalone listed entity. As a result, any SEC Form 4 insider-transaction analysis linked to ETTX should be interpreted as historical market data rather than evidence of an ongoing independent NASDAQ operating company. For SEO and investor-intelligence purposes, that distinction is essential: Entasis remains relevant primarily as a former public biotech name with a specialized antibacterial pipeline and a completed takeout. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1724344/000114036122020323/ny20004305x3_ex99-1.htm?utm_source=openai))